dual-antiplatelet therapy

Jin Coroflex Figure 1

Original Contribution

Efficacy and Safety of 3 Versus 6 Months of Dual-Antiplatelet Therapy in Patients Implanted With Coroflex ISAR Stents: A Prospective, Multicenter, Randomized Clinical Trial

07/22/2022

Seung-Woon Rha , MD, PhD;

Joon-Han Shin , MD;

Woong Chol Kang , MD;

Seung-Jea Tahk , MD, PhD;

Sang-Yong Yoo , MD;

Woo-Young Chung , MD, PhD;

Chi-Hoon Kim , MD;

Ki-Bum Won , MD;

Wook Bum Pyun , MD, PhD;

Jae Sik Jang , MD, PhD;

Moo-Hyun Kim , MD, PhD;

Soon Jun Hong , MD;

So-Yeon Choi , MD, PhD;

Yun-Seok Choi , MD;

Kyoung-Woo Seo , MD;

Hee-Yeol Kim , MD;

Hyoung-Mo Yang , MD, PhD;

Rak Kyeong Choi , MD, PhD;

Hong-Seok Lim , MD, PhD;

Eun Joo Cho , MD, PhD;

Sung Yun Lee , MD, PhD;

Byoung-Joo Choi , MD;

Young Joon Hong , MD;

Myeong-Ho Yoon , MD, PhD;

This study examined the efficacy and safety of 3- versus 6-month DAPT in patients implanted with Coroflex ISAR polymer-free DESs.

This study examined the efficacy and safety of 3- versus 6-month DAPT in patients implanted with Coroflex ISAR polymer-free DESs.

This study examined the efficacy...

07/22/2022

Journal of Invasive Cardiology

Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study

Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study

04/01/2021

Nikolaos Kakouros , MBBS, PhD, MRCP, MD(Res);

Antoine E. Soueid , MD, PharmD, JD;

Ibrahim Kassas , MD;

Jeffrey Rade , MD;

Newer antiplatelet therapy agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for...

Newer antiplatelet therapy agents are reliable and have a fast onset of action, but have significantly higher cost, leading to compliance concerns. We adopted and evaluated an acute agent-switching strategy, using prasugrel or ticagrelor for...

Newer antiplatelet therapy...

04/01/2021

Journal of Invasive Cardiology

Original Contribution

Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents – A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials

09/15/2016

Jacob A. Udell , MD, MPH;

Shaun G. Goodman , MD, MSc;

Asim N. Cheema , MD, PhD;

Akshay Bagai , MD, MHS;

Anthony W.A. Wassef , MD;

Andrew T. Yan , MD;

Current guidelines recommend 12 months of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. We investigate whether the duration of DAPT can be safely shortened with use...

Current guidelines recommend 12 months of dual-antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation. We investigate whether the duration of DAPT can be safely shortened with use...

Current guidelines recommend 12...

09/15/2016

Journal of Invasive Cardiology

Featured CME Course

Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes

Upcoming Events

February 2 ⁠–⁠ February 5

February 7 ⁠–⁠ February 9

February 27 ⁠–⁠ March 1

DCLF

March 17 ⁠–⁠ March 19

March 22 ⁠–⁠ March 23

NP Institute

March 27 ⁠–⁠ March 30

March 31 ⁠–⁠ April 2

April 21 ⁠–⁠ April 24

April 30 ⁠–⁠ May 4

WoundCon

May 1 ⁠–⁠ May 3

See Full Calendar